• Print

Details

Published: Tuesday, 14 November 2023 06:35

Written by 340B Editor

Novo Nordisk announced on its website it will discontinue Levemir in the U.S. by the end of 2024.

The decision was driven by “global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options,” Novo said in a posting on its website. “We will continue to provide Levemir FlexPen and Levemir vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected.”

FlexPen supplies will see disruptions starting in mid-January 2024, leading up to the product’s complete discontinuation by April 1, 2024. Levemir vials will continue to be available beyond that until the full brand is discontinued on Dec. 31, 2024.

Usage of this basal insulin has been trending lower over the years due to its shorter duration of action compared to available alternatives, such as Basaglar, Tresiba, Lantus, Toujeo, or their generics. It is anticipated that there will be a shift in the preferred basal insulins for Medicare plans starting in January, with potential changes in Medicaid as well. Further details will be provided in upcoming communications.

It's important to note that Lantus is currently the lowest-cost alternative under the 340B program. Please consider not initiating new patients on Levemir in the coming months, as it may require a switch next year.

Natalia Puccinelli, PharmD, BCACP, BC-ADM
Clinical Pharmacist
Community Health Centers of Lane County
2073 Olympic Street
Springfield, OR 97477-3413